AU2020290995B2 - Topical treatment of vitiligo by a JAK inhibitor - Google Patents

Topical treatment of vitiligo by a JAK inhibitor

Info

Publication number
AU2020290995B2
AU2020290995B2 AU2020290995A AU2020290995A AU2020290995B2 AU 2020290995 B2 AU2020290995 B2 AU 2020290995B2 AU 2020290995 A AU2020290995 A AU 2020290995A AU 2020290995 A AU2020290995 A AU 2020290995A AU 2020290995 B2 AU2020290995 B2 AU 2020290995B2
Authority
AU
Australia
Prior art keywords
week
vitiligo
patient
ruxolitinib
cream
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020290995A
Other languages
English (en)
Other versions
AU2020290995A1 (en
Inventor
Kathleen Butler
Michael Howell
Fiona Kuo
Jim Lee
Kang Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73651112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020290995(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2020290995A1 publication Critical patent/AU2020290995A1/en
Application granted granted Critical
Publication of AU2020290995B2 publication Critical patent/AU2020290995B2/en
Priority to AU2026200410A priority Critical patent/AU2026200410A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020290995A 2019-06-10 2020-06-10 Topical treatment of vitiligo by a JAK inhibitor Active AU2020290995B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026200410A AU2026200410A1 (en) 2019-06-10 2026-01-21 Topical treatment of vitiligo by a jak inhibitor

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201962859584P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859495P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US62/859,532 2019-06-10
US62/859,495 2019-06-10
US62/859,584 2019-06-10
US62/859,506 2019-06-10
US62/859,601 2019-06-10
US201962894514P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894564P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894496P 2019-08-30 2019-08-30
US62/894,581 2019-08-30
US62/894,496 2019-08-30
US62/894,514 2019-08-30
US62/894,541 2019-08-30
US62/894,564 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US62/911,845 2019-10-07
US202062967879P 2020-01-30 2020-01-30
US62/967,879 2020-01-30
PCT/US2020/036985 WO2020252012A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026200410A Division AU2026200410A1 (en) 2019-06-10 2026-01-21 Topical treatment of vitiligo by a jak inhibitor

Publications (2)

Publication Number Publication Date
AU2020290995A1 AU2020290995A1 (en) 2022-04-07
AU2020290995B2 true AU2020290995B2 (en) 2025-12-11

Family

ID=73651112

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020290995A Active AU2020290995B2 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a JAK inhibitor
AU2026200410A Pending AU2026200410A1 (en) 2019-06-10 2026-01-21 Topical treatment of vitiligo by a jak inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026200410A Pending AU2026200410A1 (en) 2019-06-10 2026-01-21 Topical treatment of vitiligo by a jak inhibitor

Country Status (9)

Country Link
US (4) US20200405627A1 (https=)
EP (1) EP3982971A4 (https=)
JP (2) JP7532511B2 (https=)
AU (2) AU2020290995B2 (https=)
CA (1) CA3150975A1 (https=)
IL (1) IL290637A (https=)
MA (1) MA56215A (https=)
TW (1) TW202112377A (https=)
WO (1) WO2020252012A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102821964B1 (ko) 2017-11-03 2025-06-19 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
CN119080779A (zh) 2018-08-10 2024-12-06 阿克拉瑞斯治疗股份有限公司 吡咯并嘧啶itk抑制剂
JP7532511B2 (ja) 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療
WO2022061351A1 (en) * 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
TW202302104A (zh) * 2021-02-18 2023-01-16 美商阿克拉里斯醫療股份有限公司 Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法
CN117279915A (zh) * 2021-02-18 2023-12-22 阿克拉瑞斯治疗股份有限公司 Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法
EP4389114A4 (en) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd LOCAL TOPICAL FORMULATION CONTAINING A JAK INHIBITOR OR A SALT THEREOF OR A CRYSTALLINE FORM THEREOF, PREPARATION METHOD THEREOF AND CORRESPONDING APPLICATION
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200786A1 (en) * 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
DE60213842T2 (de) 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1542768A1 (en) 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
AU2017358703A1 (en) 2016-11-10 2019-05-09 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
JP7532511B2 (ja) * 2019-06-10 2024-08-13 インサイト・コーポレイション Ｊａｋ阻害剤による尋常性白斑の局所治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200786A1 (en) * 2017-04-26 2018-11-01 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID ROSAMARIN: "Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B", 1 June 2018 (2018-06-01), pages 1205 - 1207 *
ROTHSTEIN, B ET AL.: "Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib", 2015, JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 76, no. 6, 5 April 2017, pages 1054-1060, DOI: 10.1016/j.jaad.2017.02.049 *

Also Published As

Publication number Publication date
AU2026200410A1 (en) 2026-02-12
MA56215A (fr) 2022-04-20
US20230355628A1 (en) 2023-11-09
US20200383986A1 (en) 2020-12-10
US20220409622A1 (en) 2022-12-29
WO2020252012A1 (en) 2020-12-17
AU2020290995A1 (en) 2022-04-07
US11590138B2 (en) 2023-02-28
TW202112377A (zh) 2021-04-01
JP2024105436A (ja) 2024-08-06
US11602536B2 (en) 2023-03-14
US12233067B2 (en) 2025-02-25
EP3982971A1 (en) 2022-04-20
EP3982971A4 (en) 2023-08-16
IL290637A (en) 2022-04-01
JP7532511B2 (ja) 2024-08-13
US20200405627A1 (en) 2020-12-31
CA3150975A1 (en) 2020-12-17
JP2022545568A (ja) 2022-10-27

Similar Documents

Publication Publication Date Title
US12233067B2 (en) Topical treatment of vitiligo by a JAK inhibitor
KR20140004186A (ko) 표면활성제 조성물
US20220387447A1 (en) Formulations of testosterone and methods of treatment therewith
KR102514657B1 (ko) 테스토스테론의 제형 및 이를 이용한 치료 방법
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US12589096B2 (en) Ruxolitinib formulation for reduction of itch in atopic dermatitis
US11878008B2 (en) Composition for preventing or treating atopic dermatitis
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
RS60365B1 (sr) Lečenje alopecije areate
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak
KR20150095772A (ko) 아토피성 피부염 치료를 위한 피도티모드의 사용
GB2616294A (en) Composition for use

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 10 MAR 2022

FGA Letters patent sealed or granted (standard patent)